Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

This study is comparing two medications used to treat anemia in patients with end-stage kidney disease who are on dialysis. It compares BCD-131 (a biosimilar drug) against Mircera (a well-established anemia treatment), both of which stimulate the body to make more red blood cells. The goal is to show that BCD-131 is just as effective and safe as Mircera. **You may be eligible if...** - You are aged 18–75 with documented end-stage kidney disease - You have been on dialysis for at least 90 days (hemodialysis at least 3 times a week, or peritoneal dialysis) - You have been using a specific form of erythropoietin (epoetin alfa or similar) as your current anemia treatment - You have stable hemoglobin levels within the required range **You may NOT be eligible if...** - You have not been on dialysis for at least 90 days - You are not currently on an erythropoiesis-stimulating agent - You are pregnant or breastfeeding - You have uncontrolled hypertension or recent cardiovascular events Talk to your doctor to see if this trial is right for you.